What does the product information say about breastfeeding during treatment with bevacizumab gamma (Lytenava)?

For bevacizumab gamma (Lytenava), data on human milk, breastfed infants and milk production/excretion are unavailable and infant risk cannot be excluded, so a decision must be made to discontinue breastfeeding or abstain from therapy, considering breastfeeding benefits for the child and treatment benefits for the woman.